196 related articles for article (PubMed ID: 34452926)
1. Simultaneous Engagement of Tumor and Stroma Targeting Antibodies by Engineered NK-92 Cells Expressing CD64 Controls Prostate Cancer Growth.
Hintz HM; Snyder KM; Wu J; Hullsiek R; Dahlvang JD; Hart GT; Walcheck B; LeBeau AM
Cancer Immunol Res; 2021 Nov; 9(11):1270-1282. PubMed ID: 34452926
[TBL] [Abstract][Full Text] [Related]
2. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
3. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
4. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
[TBL] [Abstract][Full Text] [Related]
5. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
Front Immunol; 2022; 13():841859. PubMed ID: 35281028
[TBL] [Abstract][Full Text] [Related]
6. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
9. iNK-CD64/16A cells: a promising approach for ADCC?
Walcheck B; Wu J
Expert Opin Biol Ther; 2019 Dec; 19(12):1229-1232. PubMed ID: 31510805
[No Abstract] [Full Text] [Related]
10. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
11. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
12. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.
Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H
MAbs; 2013; 5(4):587-94. PubMed ID: 23770975
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
[TBL] [Abstract][Full Text] [Related]
15. Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography.
Hintz HM; Gallant JP; Vander Griend DJ; Coleman IM; Nelson PS; LeBeau AM
Clin Cancer Res; 2020 Sep; 26(18):4882-4891. PubMed ID: 32636317
[TBL] [Abstract][Full Text] [Related]
16. Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy.
Ochi F; Fujiwara H; Tanimoto K; Asai H; Miyazaki Y; Okamoto S; Mineno J; Kuzushima K; Shiku H; Barrett J; Ishii E; Yasukawa M
Cancer Immunol Res; 2014 Mar; 2(3):249-62. PubMed ID: 24778321
[TBL] [Abstract][Full Text] [Related]
17. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
18. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
Laurent S; Queirolo P; Boero S; Salvi S; Piccioli P; Boccardo S; Minghelli S; Morabito A; Fontana V; Pietra G; Carrega P; Ferrari N; Tosetti F; Chang LJ; Mingari MC; Ferlazzo G; Poggi A; Pistillo MP
J Transl Med; 2013 May; 11():108. PubMed ID: 23634660
[TBL] [Abstract][Full Text] [Related]
19. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
20. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
